Opko Health (OPK) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Opko Health (OPK) Tops Q2 EPS by 3c
August 13, 2014 7:54 AM EDT
Jefferies analyst Eun K. Yang, Ph.D trimmed his price target on Buy-rated Opko Health (NYSE: OPK) to $10.50 (from $11.00) following Q2 results but maintained a Buy rating.
Yang commented, "Narrower 2Q14 net loss of $25.5M (vs. ours of $31.8M) primarily on... More
August 11, 2014 4:31 PM EDT
OPKO Health, Inc. (NYSE: OPK), announced successful top-line results from the first pivotal phase 3 trial of Rayaldee. This trial is one of two identical randomized, double-blind, placebo-controlled, multi-site studies intended to establish the safety and efficacy of Rayaldee as a new treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D... More
August 8, 2014 3:48 PM EDT
OPKO Health (NYSE: OPK) is looking to close higher for the fifth-straight session today, making a strong move back above the $9.25 in the process.
On Thursday afternoon, OPKO... More
August 7, 2014 3:49 PM EDT
OPKO Health, Inc. (NYSE: OPK), announced the submission of an Investigational New Drug (IND) Application to the United States (U.S.) Food and Drug Administration (FDA) under which Rayaldee will begin clinical evaluation as an adjunctive therapy for the prevention of skeletal-related events (SREs) in patients with bone metastases... More
